Recombinant Human CEACAM-1/CD66a Fc Chimera Avi Protein, CF Summary
Accession # P13688.2
Complete Your Research
Complete Your Experiment
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
|Formulation||Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.|
|Reconstitution||Reconstitute at 500 μg/mL in PBS.|
|Shipping||The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
When Recombinant Human CEACAM-1/CD66a (2244-CM) is immobilized at 0.5 µg/mL (100 µL/well), Biotinylated Recombinant Human CEACAM-1/CD66a Fc Chimera Avi-tag Protein (Catalog # AVI11074) binds with an ED50 of 5.00-50.0 ng/mL.
2 μg/lane of Biotinylated Recombinant Human CEACAM‑1/CD66a Fc Chimera Avi-tag Protein (Catalog # AVI11074) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 115-135 kDa and 230-270 kDa, respectively.
Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1), also known as cluster of differentiation 66a (CD66a) and biliary glycoprotein (BGP), is a member of the CEACAM subfamily of glycoproteins in the immunoglobulin (Ig) superfamily. The CEACAM family is involved in diverse cellular functions from cell adhesion and differentiation to proliferation, and survival and are utilized by several bacterial pathogens to bind and invade host cells (1-3). Mature human CEACAM-1 consists of an extracellular domain (ECD) with 1 V-type Ig-like domain and 3 C2-type Ig-like domains, a transmembrane domain, and a cytoplasmic region shows one ITIM motif and a calmodulin binding site (4). CEACAM-1 is unique among the CEACAM family as it is the only family member to contain the inhibitory ITIM domains. The ECD of human CEACAM-1 shares 54% and 52% amino acid sequence identity with mouse and rat CEACAM-1, respectively. Several alternative splice variants of CEACAM-1 have been reported with alterations occurring in both the ECD and cytoplasmic region, though the function of the isoforms remain poorly understood (5). CEACAM-1 can be expressed in human epithelial, endothelial, and hematopoietic cells and is involved in morphogenesis, apoptosis, angiogenesis, and cell proliferation as well as playing a role in innate and adaptive immunity (6,7). CEACAM-1 functions through either homophilic interactions with CEACAM-1 variants or binds in a heterophilic manner to other CEACAMs, including CEACAM-5, CEACAM-6, and CEACAM-8 (7). Several pathogens from Escherichia coli and Neisseria gonorrhoeae to N. meningitidis use CEACAM-1 as a ligand as a step in bacterial invasion of the host (8). CEACAM-1 signaling is associated with inhibition of proliferation and misregulation of its expression is often reported in cancer (5,9,10). As such, CEACAM-1 is being studied as a clinical biomarker and/or promising therapeutic target for several cancer types including: non-small cell lung cancer, pancreatic, colorectal, bladder, and melanomas (5,9,10). Our Avi-tag Biotinylated CEACAM-1 features biotinylation at a single site contained within the Avi-tag, a unique 15 amino acid peptide. Protein orientation will be uniform when bound to streptavidin-coated surface due to the precise control of biotinylation and the rest of the protein is unchanged so there is no interference in the protein's bioactivity.
- Tchoupa, A. et al. (2014) J Cell Commun Signal 12:27.
- Hauck, C.R. et al. (2006) Eur J Cell Biol. 85:235.
- Kuespert, K. et al. (2006) Curr. Opin. Cell Biol 18:565.
- Kim, W.M. et al. (2019) Seminars in immunology 42:101296.
- Dankner, M. et al. (2017) Oncoimmunology. 6:e1328336.
- Gandhi, A.K. et al. (2021) Commun Biol 4:360.
- Helfrich, I. and Singer, B.B. (2019) Cancers, 11:356.
- Voges, M. et al. (2010) BMC Microbiol. 10:117.
- Beauchemin, N. and Arabzadeh, A. (2013) Cancer Metastasis Rev. 32:643.
- Fiori, V. et al. (2012) Ann Ist Super Sanita. 48:161.
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Supplemental Cell Selection Products
Supplemental ELISA Products
Reviews for Recombinant Human CEACAM-1/CD66a Fc Chimera Avi Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human CEACAM-1/CD66a Fc Chimera Avi Protein, CF and earn rewards!
Have you used Recombinant Human CEACAM-1/CD66a Fc Chimera Avi Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image